MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo boost.
ANN ARBOR, Mich. – Resurrecting the Prelude is a loaded proposition. It’s a heady name that carries the weight of history and expectations of a fan base that has specific needs. After a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback